11:15 AM EDT, 04/03/2024 (MT Newswires) -- Merck ( MRK ) and Daiichi Sankyo said Wednesday they have dosed the first patient in a phase 2/3 trial assessing the efficacy and safety of investigational drug raludotatug deruxtecan to potentially treat ovarian cancer resistant to platinum-based chemotherapy.

The second phase of the study is being done to establish the dose of the drug candidate that will be used in the phase 3 portion, which will assess the drug candidate, compared with the investigator's choice of chemotherapy, the companies said.

The drug was discovered by Daiichi Sankyo and is being developed with Merck ( MRK ), the companies said.

Price: 130.82, Change: +0.47, Percent Change: +0.36